Pharmacotherapies for Central Post-Stroke Pain: A Systematic Review and Network Meta-Analysis
Table 2
Pairwise comparisons of treatments.
Amitriptyline
-0.07 (-0.79; 0.64)
.
.
.
.
.
.
.
.
-0.24 (-0.72; 0.24)
.
.
-0.08 (-0.75; 0.58)
Carbamazepine
.
.
.
.
.
.
.
.
-0.15 (-0.87; 0.57)
.
.
0.68 (-0.33; 1.68)
0.76 (-0.35; 1.86)
Etanercept
.
.
.
.
.
.
.
-0.92 (-1.80; -0.03)
.
.
0.08 (-0.79; 0.95)
0.17 (-0.82; 1.15)
-0.59 (-1.74; 0.55)
Ketamin
.
.
.
.
.
.
-0.32 (-1.05; 0.41)
.
.
1.15 (0.21; 2.10)
1.24 (0.18; 2.29)
0.48 (-0.72; 1.68)
1.07 (-0.02; 2.16)
Lamotrigine
.
.
.
.
.
-1.39 (-2.21; -0.58)
.
.
1.88 (0.89; 2.86)
1.96 (0.87; 3.04)
1.20 (-0.03; 2.43)
1.79 (0.67; 2.92)
0.72 (-0.46; 1.90)
Levetiracetam
.
.
.
.
-2.11 (-2.97; -1.26)
.
.
0.41 (-0.45; 1.27)
0.49 (-0.48; 1.46)
-0.27 (-1.40; 0.86)
0.33 (-0.69; 1.34)
-0.75 (-1.83; 0.34)
-1.47 (-2.58; -0.35)
Lidocaine
.
.
.
-0.65 (-1.36; 0.06)
.
.
0.41 (-0.47; 1.28)
0.49 (-0.50; 1.48)
-0.27 (-1.42; 0.88)
0.32 (-0.71; 1.36)
-0.75 (-1.84; 0.35)
-1.47 (-2.60; -0.34)
-0.00 (-1.02; 1.02)
Morphine
.
.
-0.65 (-1.38; 0.09)
.
.
-0.22 (-1.00; 0.57)
-0.13 (-1.04; 0.77)
-0.89 (-1.97; 0.19)
-0.30 (-1.26; 0.66)
-1.37 (-2.39; -0.35)
-2.09 (-3.15; -1.03)
-0.62 (-1.57; 0.32)
-0.62 (-1.58; 0.34)
Naloxone
.
-0.02 (-0.64; 0.60)
.
.
2.19 (0.98; 3.40)
2.27 (0.97; 3.57)
1.51 (0.09; 2.93)
2.11 (0.78; 3.43)
1.03 (-0.34; 2.41)
0.31 (-1.09; 1.72)
1.78 (0.46; 3.10)
1.78 (0.45; 3.12)
2.40 (1.13; 3.68)
Pamidronate
.
-0.05 (-0.91; 0.81)
.
-0.24 (-0.72; 0.24)
-0.16 (-0.82; 0.51)
-0.92 (-1.80; -0.03)
-0.32 (-1.05; 0.41)
-1.39 (-2.21; -0.58)
-2.11 (-2.97; -1.26)
-0.65 (-1.36; 0.06)
-0.65 (-1.38; 0.09)
-0.02 (-0.64; 0.60)
-2.43 (-3.54; -1.31)
Placebo
2.38 (1.67; 3.09)
0.46 (0.22; 0.71)
2.14 (1.28; 3.00)
2.22 (1.25; 3.19)
1.46 (0.33; 2.60)
2.06 (1.04; 3.07)
0.99 (-0.10; 2.07)
0.26 (-0.85; 1.38)
1.73 (0.73; 2.74)
1.73 (0.71; 2.75)
2.36 (1.41; 3.30)
-0.05 (-0.91; 0.81)
2.38 (1.67; 3.09)
Prednisone
.
0.23 (-0.31; 0.76)
0.31 (-0.40; 1.02)
-0.45 (-1.37; 0.46)
0.14 (-0.63; 0.91)
-0.93 (-1.78; -0.08)
-1.65 (-2.54; -0.76)
-0.18 (-0.94; 0.57)
-0.18 (-0.96; 0.59)
0.44 (-0.23; 1.11)
-1.96 (-3.10; -0.82)
0.46 (0.22; 0.71)
-1.91 (-2.67; -1.16)
Pregabalin
Footnotes: The comparisons between any two treatments should be read from left to right, and the comparison estimate (expressed as standard mean difference [SMD] and its related 95%CI) is in the cell between the column-defining treatment and the row-defining treatment. The top half of the table presents SMDs from direct comparison evidence, while the bottom half of the table presents SMDs from network meta-analysis. In top half, SMDs >0 favor row-defining treatments vs. column-defining treatments. In the bottom half, SMDs <0 favor column-defining treatments. Empty cells indicate no direct comparison between two treatments.
